Caribou Biosciences (CRBU) Q3 2026 earnings summary

Executive summary

• Oct. 6 Board-approved restructuring includes a strategic alternatives review, planned discontinuation of vispa-cel and CB-011, a substantial workforce reduction and other cost cuts.

• Alternatives may include a merger, acquisition, business combination, dissolution or liquidation; no timeline or transaction is assured.

• A transaction committee was formed and Wedbush Securities engaged as exclusive financial advisor.

Financial highlights

• Q3 revenue was $1.6M vs. $2.2M YoY; 9M revenue was $5.5M vs. $7.2M.

• Q3 operating loss was $27.6M vs. $29.4M and net loss was $26.6M vs. $27.5M; 9M operating loss was $79.3M vs. $119.9M and net loss was $76.0M vs. $121.6M.

• Q3 R&D expense was $21.3M vs. $22.4M; 9M R&D expense was $60.9M vs. $85.6M. Q3 G&A was $7.9M vs. $9.2M; 9M G&A was $23.9M vs. $29.3M.

• Basic and diluted loss per share was $0.25 in Q3 vs. $0.30 YoY and $0.75 for 9M vs. $1.31.

Outlook and guidance

• Cash, cash equivalents and marketable securities of $94.8M at Sept. 30 are expected to fund the current operating plan for at least 12 months from the filing date.

• Estimated 2026 restructuring costs are $15M-$19M, including $10M-$11M for severance and related costs and $5M-$8M to wind down two trials; a substantial portion is expected in Q4.

• Additional costs may arise from lease actions, contract and license terminations, or long-lived asset impairments; amounts are not yet estimated.